FILTER

FILTERED INTERVIEW RESULTS

Dr. Siva Samy

CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
ValGenesis explains how it streamlines the validation process to allow real-time access to validation documents and data enabling various stakeholders to achieve compliance efficiently.

Michael Kauffman

CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.

Eric Ostertag M.D., Ph.D.

CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.

Amit Munshi

PRESIDENT & CEO, ARENA PHARMACEUTICALS
Arena Pharmaceuticals speaks to GBR about building its pipeline and infrastructure.

Dr. Andrea Pfeifer

CO-FOUNDER & CEO, AC IMMUNE
AC Immune describes its research into neurodegenerative diseases.

Mark Egerton

CEO, QUOTIENT SCIENCES
Quotient Sciences is a drug development and manufacturing accelerator that supports pharmaceutical and biotech companies with services spanning the entire development pathway from candidate selection to commercial launch.

Jay Shukla

PRESIDENT & CEO, NIVAGEN PHARMACEUTICALS, INC.
Nivagen Pharmaceuticals provides complete research, analytical formulation development, and regulatory support.

Dr. Jagadeesh Babu Rangisetty

FOUNDER & CEO, BIOPHORE
Biophore explains how it is expanding productions of different APIs to ensure both quality and supply chain security.

James Gale

CEO, SIGNET HEALTHCARE PARTNERS
Signet Healthcare Partners speaks to GBR about how it is evolving its’ investment portfolio in life sciences.

Emer Leahy

PRESIDENT AND CEO, PSYCHOGENICS
PsychoGenics explains how CNS is attracting unprecedented attention and how its AI-driven phenotypic discovery platforms can help to deliver cures.

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2022 - Digital Version

PARTNER EVENTS